Analytical methods | ||
|---|---|---|
| Comparative study | #1 | |
| Chromatography | GC | |
| Ion source | – | |
| Positive/Negative mode | – | |
| Mass analyzer | – | |
| Identification level | – | |
Sample information | ||
|---|---|---|
| Comparative study | #1 | |
| Country | China | |
| Specimen | serum | |
| Marker function | diagnosis | |
| Participants(Case) | Cancer type | lung cancer |
| Stage | I, II, III, IV | |
| Number | 31 | |
| Gender (M,F) | 21, 10 | |
| Mean age (range) (M,F) | 54.1 ± 9.9 | |
| Smoking status | smoker, non-smoker | |
| Participants(Control) | Type | healthy |
| Number | 29 | |
| Gender (M,F) | 15, 14 | |
| Mean age (range) (M,F) | 52.1 ± 14.6 | |
| Smoking status | smoker, non-smoker | |
Data processing and metabolite identification | |
|---|---|
| Data processing software | – |
| Database search | BinBase, KEGG |
Statistical analysis | |
|---|---|
| Differential analysis method | Student t test, PLS-DA |
| Classification method | ROC curve analysis |
| Survival analysis method | – |
| Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
|---|---|---|---|---|---|---|---|
| salicylic acid | – | – | – | 5.81 | 6.46e-05 | 9.09e-04 | 0.84 |
| paracetamol | – | – | – | 4.73 | 2.86e-11 | 1.21e-10 | 1.23 |
| threitol | – | – | – | 4.05 | 1.06e-10 | 3.58e-09 | 1.35 |
| adenosine-5-phosphate | – | – | – | 3.86 | 2.20e-11 | 1.21e-09 | 1.30 |
| 2-hydroxyhippuric acid | – | – | – | 3.83 | 3.07e-08 | 7.42e-07 | 0.86 |
| azelaic acid | – | – | – | 2.39 | 4.55e-04 | 4.05e-03 | 0.65 |
| oleic acid | – | – | – | 2.20 | 8.95e-06 | 1.51e-04 | 0.73 |
| palmitoleic acid | – | – | – | 2.13 | 1.05e-04 | 1.37e-03 | 0.73 |
| butane-2,3-diol | – | – | – | 2.12 | 5.81e-05 | 8.93e-04 | 0.76 |
| kynurenine | – | – | – | 1.87 | 2.20e-04 | 2.41e-03 | 0.55 |
| maltose | – | – | – | 1.72 | 2.28e-04 | 2.41e-03 | 0.52 |
| 3-phosphoglycerate | – | – | – | 1.60 | 4.04e-03 | 0.03 | 0.24 |
| urea | – | – | – | 1.53 | 2.76e-04 | 2.60e-03 | 0.16 |
| dodecanol | – | – | – | 0.73 | 1.64e-03 | 0.01 | 1.02 |
| naproxen | – | – | – | 0.72 | 1.28e-04 | 1.54e-03 | 1.18 |
| cystine | – | – | – | 0.72 | 4.62e-03 | 0.03 | 1.05 |
| caprylic acid | – | – | – | 0.67 | 1.29e-03 | 0.01 | 1.01 |
| lyxose | – | – | – | 0.54 | 2.62e-04 | 2.60e-03 | 1.07 |
| inosine | – | – | – | 0.54 | 6.73e-06 | 1.26e-04 | 1.27 |
| oxalic acid | – | – | – | 0.45 | 1.93e-09 | 5.43e-08 | 1.40 |
| fructose | – | – | – | 0.40 | 4.50e-06 | 9.51e-05 | 1.29 |
| indole-3-acetate | – | – | – | 0.25 | 3.62e-18 | 6.12e-16 | 1.69 |
| erythritol | V | – | – | 0.21 | 2.58e-17 | 2.18e-15 | 1.67 |
| Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| salicylic acid | – | – | – | – | – | – |
| paracetamol | – | – | – | – | – | – |
| threitol | – | – | – | – | – | – |
| adenosine-5-phosphate | – | – | – | – | – | – |
| 2-hydroxyhippuric acid | – | – | – | – | – | – |
| azelaic acid | – | – | – | – | – | – |
| oleic acid | – | – | – | – | – | – |
| palmitoleic acid | – | – | – | – | – | – |
| butane-2,3-diol | – | – | – | – | – | – |
| kynurenine | – | – | – | – | – | – |
| maltose | – | – | – | – | – | – |
| 3-phosphoglycerate | – | – | – | – | – | – |
| urea | – | – | – | – | – | – |
| dodecanol | – | – | – | – | – | – |
| naproxen | – | – | – | – | – | – |
| cystine | – | – | – | – | – | – |
| caprylic acid | – | – | – | – | – | – |
| lyxose | – | – | – | – | – | – |
| inosine | – | – | – | – | – | – |
| oxalic acid | – | – | – | – | – | – |
| fructose | – | – | – | – | – | – |
| indole-3-acetate | – | – | – | – | – | – |
| erythritol | V | – | (0.914, 1.000) | 93.1 | 100 | – |